Coherus Oncology (CHRS) Current Deferred Revenue (2013 - 2017)

Coherus Oncology has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $669000.0 for Q1 2017.

• In Q1 2017, Current Deferred Revenue fell 98.65% year-over-year to $669000.0; the TTM figure through Mar 2017 stood at $669000.0 (down 98.65% YoY), while the FY2016 annual figure was $892000.0, down 98.2% from the prior year.
• Current Deferred Revenue came in at $669000.0 for Q1 2017 at Coherus Oncology, down from $892000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $61.3 million in Q2 2016 to a low of $300000.0 in Q1 2014.
• Average Current Deferred Revenue over 5 years is $23.7 million, with a median of $22.8 million recorded in 2014.
• Year-over-year, Current Deferred Revenue jumped 7500.0% in 2015 and tumbled 98.65% in 2017.
• Over 5 years, Current Deferred Revenue stood at $14.3 million in 2013, then jumped by 59.63% to $22.8 million in 2014, then soared by 117.64% to $49.6 million in 2015, then sank by 98.2% to $892000.0 in 2016, then declined by 25.0% to $669000.0 in 2017.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $669000.0 in Q1 2017, $892000.0 in Q4 2016, and $1.4 million in Q3 2016.